- Conditions
- HR+/HER2- Breast Cancer
- Interventions
- BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2037
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 72
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- B-cell Malignancies
- Interventions
- Zanubrutinib, Tislelizumab
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 955 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 26
- States / cities
- Gilbert, Arizona • Little Rock, Arkansas • Centennial, Colorado + 23 more
- Conditions
- Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
- Interventions
- BGB-B2033, Tislelizumab, Bevacizumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 7
- States / cities
- Goodyear, Arizona • Duarte, California • Zion, Illinois + 4 more
- Conditions
- Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma
- Interventions
- BGB-21447
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Iowa City, Iowa • Waukee, Iowa + 4 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 35
- States / cities
- Laguna Hills, California • Orange, California • Palo Alto, California + 31 more
- Conditions
- Non-small Cell Lung Cancer, NSCLC
- Interventions
- Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 9
- States / cities
- Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
- Conditions
- Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
- Interventions
- zanubrutinib, bendamustine, rituximab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 12
- States / cities
- Orange, California • Chicago, Illinois • Boston, Massachusetts + 9 more
- Conditions
- HER2-amplified Biliary Tract Cancers
- Interventions
- ZW25 (Zanidatamab)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Duarte, California + 11 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Zanubrutinib, Bendamustine, Rituximab, Venetoclax
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 18
- States / cities
- Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more
- Conditions
- Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- BGB-21447, Fulvestrant, BGB-43395
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Houston, Texas • Seattle, Washington
- Conditions
- Advanced or Metastatic MTAP-deleted Solid Tumors
- Interventions
- BG-89894
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Solid Tumors, Advanced Solid Tumor
- Interventions
- BG-C0902
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Houston, Texas • San Antonio, Texas • Fairfax, Virginia
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab, Sonrotoclax, Zanubrutinib
- Procedure · Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Duarte, California • Irvine, California + 12 more
- Conditions
- Pancreatic Cancer
- Interventions
- ELI-002 7P, Tislelizumab, mFOLFIRINOX
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
- Interventions
- BGB-B3227, Tislelizumab, Chemotherapy
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Los Angeles, California • St Louis, Missouri • Hackensack, New Jersey + 2 more
- Conditions
- Solid Tumor, Adult
- Interventions
- Lifirafenib, mirdametinib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Houston, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: BG-T187, Other Therapeutic Agents
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Houston, Texas • Fairfax, Virginia + 1 more
- Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Interventions
- Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 30
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
- Conditions
- Mantle Cell Lymphoma, B Cell Lymphoma
- Interventions
- Sonrotoclax, Zanubrutinib, Placebo
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Zanubrutinib, Obinutuzumab, Sonrotoclax
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Zanubrutinib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Duarte, California + 4 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
- Interventions
- Zanubrutinib, Obinutuzumab, Venetoclax
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 8
- States / cities
- Evanston, Illinois • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
- Interventions
- Zanubrutinib, Sonrotoclax, Obinutuzumab, Catadegbrutinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York